Hainan Huluwa Pharmaceutical's (SHA:605199) zoledronic acid concentrate for injection obtained a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse filing on Saturday.
The pharmaceutical company's shares jumped 3% at the close of Monday's trade.
The drug is used in combination with standard antitumor therapy for the treatment of skeletal complications in patients with bone metastases from solid tumors and multiple myeloma.